FABRICATION OF A PROTOTYPE IMPLANTABLE GLUCOSE SENSOR

众所周知，需要一种可植入的葡萄糖传感器 糖尿病的治疗。连续不断的传感器会向用户发出警告 低血糖和改善胰岛素替代的信息 通过常规注射、机械胰岛素泵或其他方式。 我们有一个显示出希望的传感器。传感器采用固定式 葡萄糖氧化酶，连接至恒电位氧电极，操作 与氧参比电极相结合。传感器是 在过去的十五年里用系统工程发展起来的 接近。该传感器的一个简单版本已被用作中央 在狗身上植入静脉，在没有静脉移植的情况下已经工作了100多天 需要重新校准，这是长期出版的记录 性能。该传感器具有作为植入物的明显的操作潜力 持续更长的时间。然而，在许多情况下，特别是在儿童中， 组织部位可能是较好的植入部位。GlySens的目标是 生产一种不同类型的葡萄糖传感器，用于组织中。 在这个第一阶段的项目中，我们计划：(1)制作一个基于 论集成电路制造工艺的适应性(二) 制造和验证原型台式仪器，以操作 传感器；以及(3)对传感器进行广泛的体外表征和测试。 这些研究将确定影响传感器性能的因素和 一辈子。这项工作代表了我们对以前传感器的创新 设计和制造方法，是迈向商业化的必要步骤 申请。在第二阶段，传感器将在必要时进行改进。 建议的商业应用： 糖尿病的管理消耗了全国卫生保健总额的15% 支出，占医疗保险支出的25%，广告负责 巨大的人力资源成本，不计其数。这些成本可以降低 基本上是通过改善血糖控制而实现的 胰岛素替代，通过持续监测血液成为可能 葡萄糖。有数百万糖尿病患者可能 利益。

There is a well-known need for an implantable glucose sensor in the treatment of diabetes. A continuous sensor would provide users a warning of hypoglycemia and information for improved insulin replacement either by conventional injection, mechanical insulin pumps or other means. We have a sensor that shows promise. The sensor employs immobilized glucose oxidase coupled to a potentiostatic oxygen electrode, operated in conjunction with an oxygen reference electrode. The sensor was developed over the last fifteen years using a systematic engineering approach. A simple version of the sensor has been employed as a central venous implant in dogs and has functioned for more that 100 days without the need for recalibration, the standing published record for long-term performance. The sensor has clear potential for operation as an implant for longer periods. However, in many cases, especially in children, a tissue site may be preferable for implantation. GlySens' goal is to produce a different type of glucose sensor for application in tissues. In this Phase I project we plan to: (1) make a prototype sensor based on adaptation of integrated circuit fabrication technology; (2) fabricate and validate prototype benchtop instrumentation to operate the sensor; and (3) characterize and test the sensor extensively in vitro. These studies will identify factors that affect sensor performance and lifetime. This work represents innovation over our previous sensor design and fabrication methods and is a necessary step toward commercial application. In Phase II, the sensor will be refined if necessary. PROPOSED COMMERCIAL APPLICATION: The management of diabetes consumes 15% of total national health care expenditures, 25% of MediCare expenditures, ad is responsible for an enormous, untold cost in human resources. These costs could be reduced substantially by better blood glucose control resulting from improved insulin replacement, made possible by continuous monitoring of blood glucose. There are several million people with diabetes who could benefit.